Accra:The Gambia A new study has found that vaccinating entire communities with the R21 malaria vaccine before the onset of the rainy season can reduce the odds of malaria infection by up to 70%. This research, published in The Lancet, highlights the potential effectiveness of the R21 vaccine when used alongside existing malaria control measures.
According to Azerbaijan State News Agency, the study was conducted in The Gambia and Burkina Faso, regions with varying levels of malaria transmission. It demonstrated that seasonal mass vaccination with the R21/Matrix-M (R21) vaccine significantly lowered the number of individuals infected with malaria during peak transmission months. Specifically, the study revealed a 47% reduction in clinical malaria cases in The Gambia and a 30% reduction in Burkina Faso.
This research marks the first instance of vaccinating entire communities with the R21 vaccine, previously used mainly in small children. The study's findings suggest that seasonal mass vaccination could serve as a crucial tool in reducing malaria's impact and advancing efforts toward its elimination.
Umberto D'Alessandro, a professor and principal investigator of the SERVAL study at MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, emphasized the implications of the study. He noted that the R21 vaccine can effectively reduce malaria cases in older children, adolescents, and adults, challenging previous assumptions about its efficacy in these age groups.
The study involved 54 villages, with 30 in The Gambia and 24 in Burkina Faso. Half of the villages received three monthly doses of the R21 vaccine between May and August, while the other half formed the control group. Standard malaria control practices, including seasonal malaria chemoprevention, continued in both countries throughout the study.